![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ATIC |
Gene summary for ATIC |
![]() |
Gene information | Species | Human | Gene symbol | ATIC | Gene ID | 471 |
Gene name | 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase | |
Gene Alias | AICAR | |
Cytomap | 2q35 | |
Gene Type | protein-coding | GO ID | GO:0003360 | UniProtAcc | P31939 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
471 | ATIC | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.70e-05 | 4.05e-01 | -0.059 |
471 | ATIC | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.80e-03 | 3.39e-01 | 0.0674 |
471 | ATIC | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.13e-05 | 4.89e-01 | 0.294 |
471 | ATIC | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 4.05e-04 | 1.01e+00 | 0.3487 |
471 | ATIC | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.10e-10 | 6.50e-01 | 0.3859 |
471 | ATIC | A015-C-203 | Human | Colorectum | FAP | 2.10e-08 | -1.53e-01 | -0.1294 |
471 | ATIC | A001-C-108 | Human | Colorectum | FAP | 2.52e-02 | -5.31e-02 | -0.0272 |
471 | ATIC | A002-C-205 | Human | Colorectum | FAP | 4.96e-02 | -9.22e-02 | -0.1236 |
471 | ATIC | A015-C-104 | Human | Colorectum | FAP | 1.53e-06 | -3.15e-02 | -0.1899 |
471 | ATIC | A002-C-116 | Human | Colorectum | FAP | 1.68e-04 | -3.76e-02 | -0.0452 |
471 | ATIC | CRC-1-8810 | Human | Colorectum | CRC | 9.03e-03 | 3.33e-01 | 0.6257 |
471 | ATIC | LZE4T | Human | Esophagus | ESCC | 1.47e-06 | 3.67e-01 | 0.0811 |
471 | ATIC | LZE8T | Human | Esophagus | ESCC | 3.56e-04 | 2.96e-01 | 0.067 |
471 | ATIC | LZE24T | Human | Esophagus | ESCC | 2.53e-09 | 4.30e-01 | 0.0596 |
471 | ATIC | LZE6T | Human | Esophagus | ESCC | 8.91e-05 | 5.15e-01 | 0.0845 |
471 | ATIC | P1T-E | Human | Esophagus | ESCC | 1.89e-02 | 3.48e-01 | 0.0875 |
471 | ATIC | P2T-E | Human | Esophagus | ESCC | 2.71e-31 | 7.08e-01 | 0.1177 |
471 | ATIC | P4T-E | Human | Esophagus | ESCC | 9.17e-09 | 4.87e-01 | 0.1323 |
471 | ATIC | P5T-E | Human | Esophagus | ESCC | 9.39e-20 | 5.71e-01 | 0.1327 |
471 | ATIC | P8T-E | Human | Esophagus | ESCC | 4.10e-18 | 4.31e-01 | 0.0889 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003110015 | Oral cavity | LP | animal organ regeneration | 31/4623 | 76/18723 | 1.43e-03 | 1.13e-02 | 31 |
GO:004239812 | Oral cavity | LP | cellular modified amino acid biosynthetic process | 21/4623 | 46/18723 | 1.56e-03 | 1.20e-02 | 21 |
GO:004639018 | Oral cavity | LP | ribose phosphate biosynthetic process | 65/4623 | 190/18723 | 1.97e-03 | 1.47e-02 | 65 |
GO:190129315 | Oral cavity | LP | nucleoside phosphate biosynthetic process | 84/4623 | 256/18723 | 1.98e-03 | 1.47e-02 | 84 |
GO:0009259110 | Oral cavity | LP | ribonucleotide metabolic process | 120/4623 | 385/18723 | 2.15e-03 | 1.57e-02 | 120 |
GO:000916515 | Oral cavity | LP | nucleotide biosynthetic process | 83/4623 | 254/18723 | 2.38e-03 | 1.71e-02 | 83 |
GO:000657512 | Oral cavity | LP | cellular modified amino acid metabolic process | 64/4623 | 188/18723 | 2.43e-03 | 1.73e-02 | 64 |
GO:0006163110 | Oral cavity | LP | purine nucleotide metabolic process | 122/4623 | 396/18723 | 3.10e-03 | 2.11e-02 | 122 |
GO:0009150110 | Oral cavity | LP | purine ribonucleotide metabolic process | 114/4623 | 368/18723 | 3.41e-03 | 2.28e-02 | 114 |
GO:004255912 | Oral cavity | LP | pteridine-containing compound biosynthetic process | 9/4623 | 15/18723 | 3.82e-03 | 2.48e-02 | 9 |
GO:007252210 | Oral cavity | LP | purine-containing compound biosynthetic process | 66/4623 | 200/18723 | 4.84e-03 | 3.05e-02 | 66 |
GO:00061881 | Oral cavity | LP | IMP biosynthetic process | 7/4623 | 11/18723 | 7.01e-03 | 3.96e-02 | 7 |
GO:000926018 | Oral cavity | LP | ribonucleotide biosynthetic process | 60/4623 | 182/18723 | 7.12e-03 | 4.00e-02 | 60 |
GO:002198711 | Oral cavity | LP | cerebral cortex development | 40/4623 | 114/18723 | 8.25e-03 | 4.48e-02 | 40 |
GO:000616410 | Oral cavity | LP | purine nucleotide biosynthetic process | 62/4623 | 191/18723 | 9.12e-03 | 4.86e-02 | 62 |
GO:0019693112 | Skin | cSCC | ribose phosphate metabolic process | 146/4864 | 396/18723 | 9.28e-07 | 1.68e-05 | 146 |
GO:000675324 | Skin | cSCC | nucleoside phosphate metabolic process | 176/4864 | 497/18723 | 1.55e-06 | 2.62e-05 | 176 |
GO:0046390111 | Skin | cSCC | ribose phosphate biosynthetic process | 79/4864 | 190/18723 | 1.86e-06 | 3.10e-05 | 79 |
GO:000911724 | Skin | cSCC | nucleotide metabolic process | 173/4864 | 489/18723 | 2.03e-06 | 3.35e-05 | 173 |
GO:0072521112 | Skin | cSCC | purine-containing compound metabolic process | 150/4864 | 416/18723 | 2.88e-06 | 4.54e-05 | 150 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa015232 | Esophagus | ESCC | Antifolate resistance | 22/4205 | 30/8465 | 7.23e-03 | 1.76e-02 | 8.99e-03 | 22 |
hsa0152311 | Esophagus | ESCC | Antifolate resistance | 22/4205 | 30/8465 | 7.23e-03 | 1.76e-02 | 8.99e-03 | 22 |
hsa006702 | Liver | HCC | One carbon pool by folate | 17/4020 | 20/8465 | 6.04e-04 | 2.50e-03 | 1.39e-03 | 17 |
hsa01523 | Liver | HCC | Antifolate resistance | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
hsa0067011 | Liver | HCC | One carbon pool by folate | 17/4020 | 20/8465 | 6.04e-04 | 2.50e-03 | 1.39e-03 | 17 |
hsa015231 | Liver | HCC | Antifolate resistance | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATIC | SNV | Missense_Mutation | c.52N>A | p.Val18Met | p.V18M | P31939 | protein_coding | deleterious(0.01) | benign(0.425) | TCGA-AN-A0XS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ATIC | insertion | Frame_Shift_Ins | novel | c.708dupA | p.Phe237IlefsTer45 | p.F237Ifs*45 | P31939 | protein_coding | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
ATIC | SNV | Missense_Mutation | rs150438200 | c.784G>A | p.Ala262Thr | p.A262T | P31939 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ATIC | SNV | Missense_Mutation | novel | c.1027G>A | p.Ala343Thr | p.A343T | P31939 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ATIC | SNV | Missense_Mutation | novel | c.1405C>T | p.His469Tyr | p.H469Y | P31939 | protein_coding | deleterious(0.03) | possibly_damaging(0.663) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
ATIC | SNV | Missense_Mutation | novel | c.1608C>G | p.Ile536Met | p.I536M | P31939 | protein_coding | tolerated(0.05) | benign(0.007) | TCGA-VS-A8QA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ATIC | SNV | Missense_Mutation | novel | c.1579N>C | p.Trp527Arg | p.W527R | P31939 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
ATIC | SNV | Missense_Mutation | rs766526084 | c.515N>A | p.Arg172His | p.R172H | P31939 | protein_coding | deleterious(0) | possibly_damaging(0.582) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATIC | SNV | Missense_Mutation | c.1385N>T | p.Ala462Val | p.A462V | P31939 | protein_coding | tolerated(0.18) | benign(0.139) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
ATIC | SNV | Missense_Mutation | c.403N>A | p.Ala135Thr | p.A135T | P31939 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
471 | ATIC | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | FOLIC ACID | 9679969 | ||
471 | ATIC | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | METHOTREXATE | METHOTREXATE | 3860829 | |
471 | ATIC | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | PEMETREXED | PEMETREXED | 24256410 | |
471 | ATIC | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | methotrexate | METHOTREXATE | 27885916,18322994,27217051,26799664,25084201,27676277,29520081,16947783,20847201,15457444 |
Page: 1 |